Published in Immunity on March 01, 2005
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol (2005) 2.83
CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007) 2.68
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
MYC regulates the antitumor immune response through CD47 and PD-L1. Science (2016) 1.87
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Recent developments in cancer vaccines. J Immunol (2011) 1.76
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Chemokines in health and disease. Exp Cell Res (2011) 1.69
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS One (2014) 1.45
Dendritic cells and immunity against cancer. J Intern Med (2011) 1.32
CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood (2007) 1.31
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res (2012) 1.20
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood (2007) 1.18
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol (2014) 1.14
Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J Clin Invest (2014) 1.13
Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol (2014) 1.07
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A (2010) 1.06
Aire deficiency promotes TRP-1-specific immune rejection of melanoma. Cancer Res (2013) 1.06
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med (2007) 1.05
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther (2013) 1.04
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood (2010) 1.03
Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules. PLoS One (2008) 1.03
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol (2012) 0.99
Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology (2012) 0.97
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology (2009) 0.97
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96
Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood (2009) 0.96
An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol (2012) 0.95
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood (2008) 0.95
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol (2012) 0.94
Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model. Int J Cancer (2011) 0.93
Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility. Am J Respir Cell Mol Biol (2006) 0.92
Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant (2007) 0.92
CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology (2007) 0.90
Dendritic cells: are they clinically relevant? Cancer J (2010) 0.90
Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene (2014) 0.89
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology (2013) 0.88
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology (2014) 0.87
The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells. Inflamm Res (2012) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses. PLoS One (2014) 0.85
Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology (2013) 0.84
Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs. J Comput Aided Mol Des (2010) 0.84
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy. Int J Mol Sci (2014) 0.84
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol (2011) 0.83
Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol (2010) 0.81
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One (2014) 0.81
Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med (2009) 0.80
Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. PLoS One (2010) 0.80
In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun (2009) 0.80
The aging immune system and its relationship with cancer. Aging health (2011) 0.79
Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology (2009) 0.79
Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol (2015) 0.79
Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure. J Immunol (2010) 0.79
IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. Oncoimmunology (2016) 0.78
Targeting c-MYC with T-cells. PLoS One (2013) 0.78
Harnessing dendritic cells for tumor antigen presentation. Cancers (Basel) (2011) 0.78
A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One (2012) 0.78
Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA. BMC Biotechnol (2010) 0.78
Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cell Immunol (2007) 0.78
Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE). PLoS One (2009) 0.78
Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells. Oncotarget (2016) 0.77
Myeloid neighborhood in myeloma: cancer's underbelly? Am J Hematol (2009) 0.77
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma. Leukemia (2015) 0.77
Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. J Immunother (2013) 0.77
Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology (2013) 0.77
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncoimmunology (2015) 0.76
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Oncotarget (2016) 0.76
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS One (2012) 0.76
Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. Immunol Cell Biol (2016) 0.76
Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells. Sci Rep (2015) 0.76
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer. Haematologica (2012) 0.76
Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget (2016) 0.76
Metastatic melanoma cells evade immune detection by silencing STAT1. Int J Mol Sci (2015) 0.75
High CD4(+) T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer. Int J Clin Exp Pathol (2015) 0.75
Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen. Oncoimmunology (2014) 0.75
Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. J Immunother Cancer (2015) 0.75
Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions. Oncol Lett (2017) 0.75
Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens. PLoS One (2013) 0.75
Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma. PLoS One (2015) 0.75
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature (2017) 0.75
Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A (2003) 3.98
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J (2006) 3.07
Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol (2003) 2.72
Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol (2008) 1.76
Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood (2004) 1.61
A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J Exp Med (2005) 1.54
Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood (2004) 1.50
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J Immunol (2011) 1.39
The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. J Leukoc Biol (2009) 1.25
Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol (2010) 1.21
Characterization of a novel chemokine-containing storage granule in endothelial cells: evidence for preferential exocytosis mediated by protein kinase A and diacylglycerol. J Immunol (2005) 1.20
Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol (2003) 1.13
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol (2008) 1.06
Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol (2005) 1.05
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med (2007) 1.05
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res (2009) 1.03
Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep (2013) 1.02
Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood (2005) 1.01
Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol (2007) 1.01
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol (2012) 1.00
Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One (2012) 0.96
Vascular morphogenesis and differentiation after adoptive transfer of human endothelial cells to immunodeficient mice. Am J Pathol (2002) 0.95
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood (2007) 0.94
The alarmin IL-33 is a notch target in quiescent endothelial cells. Am J Pathol (2012) 0.94
A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol (2002) 0.93
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 0.93
Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther (2004) 0.93
MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol (2004) 0.93
Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur J Immunol (2014) 0.93
TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8α+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques. J Immunol (2014) 0.91
DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 0.91
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol (2012) 0.91
Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol (2004) 0.90
Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J (2005) 0.89
Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood (2004) 0.89
Liprin (beta)1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity. Blood (2009) 0.89
Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer (2011) 0.88
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells. Eur J Immunol (2014) 0.87
Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies. J Biol Chem (2009) 0.86
The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol (2010) 0.86
Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage. PLoS One (2011) 0.86
Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease. J Immunol (2005) 0.86
Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunol Lett (2013) 0.86
DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol (2013) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Endostatin suppresses IGF-II-mediated signaling and invasion of human extravillous trophoblasts. Endocrinology (2011) 0.85
Cytokine secretion depends on Galalpha(1,3)Gal expression in a pig-to-human whole blood model. J Immunol (2008) 0.84
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems. Am J Pathol (2009) 0.84
Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology (2013) 0.84
Family-with-sequence-similarity-46, member A (Fam46a) gene is expressed in developing tooth buds. Arch Oral Biol (2009) 0.83
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood (2012) 0.83
Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines. Vaccine (2010) 0.82
Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J Immunol (2002) 0.82
Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Eur J Haematol (2011) 0.82
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest (2015) 0.82
The HUVEC/Matrigel assay: an in vivo assay of human angiogenesis suitable for drug validation. Methods Mol Biol (2007) 0.82
The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS One (2013) 0.82
CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother (2004) 0.81
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine (2007) 0.81
Generation and characterization of an immortalized human mesenchymal stromal cell line. Stem Cells Dev (2014) 0.80
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS One (2012) 0.79
Human serum-induced porcine endothelial cell E-selectin expression is associated with IgG3 and IgM anti-Gal antibodies. Xenotransplantation (2002) 0.79
Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level. Mol Immunol (2007) 0.79
Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica (2006) 0.79
CD38 is a marker of human lacteals. Virchows Arch (2002) 0.79
A VH4-34+ myeloma protein with weak autoreactivity. Haematologica (2007) 0.78
Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. Eur J Immunol (2005) 0.78
Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules. Expert Rev Vaccines (2015) 0.78
Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunol Immunother (2004) 0.78
Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells. PLoS One (2012) 0.78
Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA. BMC Biotechnol (2010) 0.78
DeltaPhage--a novel helper phage for high-valence pIX phagemid display. Nucleic Acids Res (2012) 0.77
CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses. Protein Eng Des Sel (2012) 0.77
Processing of an antigenic sequence from IgG constant domains for presentation by MHC class II. J Immunol (2008) 0.77
Expanding the versatility of phage display I: efficient display of peptide-tags on protein VII of the filamentous phage. PLoS One (2011) 0.77
Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation. Xenotransplantation (2006) 0.76
Induction of central T cell tolerance: recombinant antibodies deliver peptides for deletion of antigen-specific (CD4+)8+ thymocytes. Eur J Immunol (2005) 0.76
Antibody-mediated delivery of antigen to chemokine receptors on antigen-presenting cells results in enhanced CD4+ T cell responses. Eur J Immunol (2003) 0.76
Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins. BMC Biotechnol (2010) 0.76
The idiotype connection: linking infection and multiple sclerosis. Trends Immunol (2009) 0.76
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS One (2012) 0.76
Recombinant antibodies for delivery of antigen: a single loop between beta-strands in the constant region can accommodate long, complex and tandem T cell epitopes. Int Immunol (2008) 0.76
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. J Transl Med (2014) 0.75
Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells. J Immunol (2014) 0.75